Találati lista | Tudóstér

001-es BibID:	BIBFORM118904
035-os BibID:	(Scopus)85188726976 (WoS)001191781000001
Első szerző:	Nagy Nikolett (belgyógyász)
Cím:	Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus / Nagy Nikolett, Bói Bernadett, Papp Gábor, Fiák Edit, Gáspár-Kiss Eszter, Perge Bianka, Farmasi Nikolett, Tarr Tünde
Dátum:	2024
ISSN:	2227-9059
Megjegyzések:	In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim of this retrospective, single-center study was to investigate the occurrence of antiphospholipid antibodies and non-thrombotic cardiac manifestations in 369 SLE patients. We also assessed the clinical and laboratory characteristics of the patients to reveal the risk factors for cardiac manifestations. Patients were divided into two groups based on the presence of antiphospholipid antibodies (APA); 258 (69.9%) patients were APA positive, and 111 (30.1%) patients were APA negative. Mitral and tricuspid insufficiency, aortic stenosis and pulmonary arterial hypertension were more common in APA-positive patients. Anticardiolipin IgG showed the strongest correlation with any non-thrombotic cardiac manifestations. Based on our results, the adjusted global antiphospholipid syndrome score (aGAPSS) above 8.5 is predictive of valvulopathies and ischemic heart disease, while aGAPSS above 9.5 is predictive of cardiomyopathies. The presence of antiphospholipid antibodies may affect the development of cardiac manifestations in SLE. Periodic cardiological and echocardiographic screening of patients without cardiac complaints, as well as regular monitoring of antiphospholipid antibodies, have great importance during the treatment of SLE patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk systemic lupus erythematosus antiphospholipid antibodies non-thrombotic cardiac manifestations aGAPSS
Megjelenés:	Biomedicines. - 12 : 3 (2024), p. 1-15. -
További szerzők:	Bói Bernadett Papp Gábor (1984-) (belgyógyász) Fiák Edit Gáspár-Kiss Eszter (1997-) (rezidens) Perge Bianka (1990-) (belgyógyász) Farmasi Nikolett (1989-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus)
Pályázati támogatás:	OTKA-124177 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM124574
035-os BibID:	(scopus)85205037927 (wos)001323012700001
Első szerző:	Perge Bianka (belgyógyász)
Cím:	Clinical Features and Survival Analysis of Lupus Nephritis among Patients with Systemic Lupus Erythematosus : a Three-Decade-Long Retrospective Cohort Study / Perge Bianka, Papp Gábor, Bói Bernadett, Nagy Nikolett, Gáspár-Kiss Eszter, Tarr Tünde
Dátum:	2024
ISSN:	2227-9059
Megjegyzések:	Background/Objectives: Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). The aim of our retrospective cohort study was to compare the clinical characteristics, therapy, survival, causes of death, and prognostic factors of LN and non-LN lupus patients. Moreover, we compared a wide spectrum of clinical data of LN patients diagnosed before and since 2005 to determine any changes in disease course and outcomes. Methods: We assessed the clinical and laboratory data of 384 SLE patients, out of whom, 127 patients were diagnosed with LN between 1990 and 2020. Results: Based on our observations, discoid LE, subacute cutaneous LE, antiphospholipid syndrome, Sjögren's syndrome, and rheumatoid arthritis were more common in non-LN patients, while anemia and anti-RNP positivity were more frequent in LN patients. Development of LN did not affect survival rates; male sex and presence of APS were negative prognostic parameters in the non-LN group while achieving remission was a positive prognostic factor in both groups. Death caused by sepsis was more prevalent in the LN group. Serositis and neurological manifestations occurred less frequently in LN patients diagnosed after 2005. The use of mycophenolate mofetil became more common, and the cumulative corticosteroid dose decreased. The SLICC Damage Index score also decreased. Conclusions: Our study demonstrated that the disease course has changed in recent years, and the main therapeutic goal in both SLE and lupus nephritis should be to achieve remission because this significantly improves long-term prognosis and patient survival.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk SLE lupus nephritis survival remission low disease activity
Megjelenés:	Biomedicines. - 12 : 9 (2024), p. 1-17. -
További szerzők:	Papp Gábor (1984-) (belgyógyász) Bói Bernadett Nagy Nikolett (1989-) (belgyógyász) Gáspár-Kiss Eszter (1997-) (rezidens) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: